ERBB2 and breast cancer: Another difficulty associated with BC treatment is planning the appropriate therapy, taking into account histological variety, hormonal dependence, eventual overexpression of estrogen receptor α (ERα), estrogen receptor β (ERβ), human epidermal growth factor receptor 2 (HER2), and resistance against conventional treatment [186].